LG-2527
LG-2527 is a nonsteroidal progestin which was under development by Ligand Pharmaceuticals and Wyeth for the treatment of menopausal symptoms and breast cancer but was never marketed.[1] It reached the preclinical stage of development prior to the discontinuation of its development in early 2001.[1]
| Clinical data | |
|---|---|
| Drug class | Progestin; Progestogen |
References
- "LG 2527 - AdisInsight". adisinsight.springer.com.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.